Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Tandon, Manish ^a   Gokul, Karthiga ^b   Ali, Syed A ^b   Chen, Zujian ^a   Lian, Jane ^b   Stein, Gary S ^b   Pratap, Jitesh ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bmp 3B; Gene silencing; Lung cancer; Runx2

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 10; HISTONE H3; HISTONE METHYLTRANSFERASE; MESSENGER RNA; OSTEOGENIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; GDF10 PROTEIN, MOUSE; METHYLTRANSFERASE; REPRESSOR PROTEIN; RUNX2 PROTEIN, MOUSE; SUV39H1 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; EPIGENETICS; GENE SILENCING; GENE TARGETING; HISTONE METHYLATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG FIBROBLAST; MESENCHYME CELL; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METHYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WOUND HEALING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL GROWTH; CELL MOTION; CYTOLOGY; GENETICS; LUNG TUMOR; MESODERM; METABOLISM; PATHOLOGY; PROMOTER REGION; SKULL; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE SILENCING; GROWTH DIFFERENTIATION FACTOR 10; LUNG NEOPLASMS; MESODERM; METHYLTRANSFERASES; MICE; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SKULL;

EID: 84862214279     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-27     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002, 3:415-428.
3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genet 1999, 21:163-167. 10.1038/5947, 9988266.
4. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764. 10.1016/S0092-8674(00)80258-5, 9182763.
5. Choi J-Y, Pratap J, Javed A, Zaidi SK, Xing L, Balint E, Dalamangas S, Boyce B, van Wijnen AJ, Lian JB, Stein JL, Jones SN, Stein GS. Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA 2001, 98:8650-8655. 10.1073/pnas.151236498, 37490, 11438701.
6. Blyth K, Cameron ER, Neil JC. The runx genes: gain or loss of function in cancer. Nat Rev Cancer 2005, 5:376-387. 10.1038/nrc1607, 15864279.
7. Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C, Soong R, Pho RW, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 2009, 36:153-158. 10.1007/s11033-008-9378-1, 2981062, 18931939.
8. Pratap J, Lian JB, Stein GS. Metastatic bone disease: role of transcription factors and future targets. Bone 2011, 48:30-36. 10.1016/j.bone.2010.05.035, 2958222, 20561908.
9. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010, 29:811-821. 10.1038/onc.2009.389, 2820596, 19915614.
10. Selvamurugan N, Partridge NC. Constitutive expression and regulation of collagenase-3 in human breast cancer cells. Mol Cell Biol Res Commun 2000, 3:218-223. 10.1006/mcbr.2000.0215, 10891395.
11. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 2006, 66:2195-2201. 10.1158/0008-5472.CAN-05-3558, 16489021.
12. Stewart M, Mackay N, Hanlon L, Blyth K, Scobie L, Cameron E, Neil JC. Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res 2007, 67:5126-5133. 10.1158/0008-5472.CAN-07-0433, 2562448, 17545590.
13. Bae SC, Lee KS, Zhang YW, Ito Y. Intimate relationship between TGF-beta/BMP signaling and runt domain transcription factor, PEBP2/CBF. J Bone Joint Surg Am 2001, 83-A(Suppl 1(Pt 1):S48-S55.
14. Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, Adams SL. Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am 2001, 83-A(Suppl 1(Pt 1)):S15-S22.
15. Takao M, Hino J, Takeshita N, Konno Y, Nishizawa T, Matsuo H, Kangawa K. Identification of rat bone morphogenetic protein-3b (BMP-3b), a new member of BMP-3. Biochem Biophys Res Commun 1996, 219:656-662. 10.1006/bbrc.1996.0289, 8605043.
16. Hino J, Takao M, Takeshita N, Konno Y, Nishizawa T, Matsuo H, Kangawa K. cDNA cloning and genomic structure of human bone morphogenetic protein-3B (BMP-3b). Biochem Biophys Res Commun 1996, 223:304-310. 10.1006/bbrc.1996.0889, 8670277.
17. Zhao R, Lawler AM, Lee SJ. Characterization of GDF-10 expression patterns and null mice. Dev Biol 1999, 212:68-79. 10.1006/dbio.1999.9326, 10419686.
18. Hino J, Matsuo H, Kangawa K. Bone morphogenetic protein-3b (BMP-3b) gene expression is correlated with differentiation in rat calvarial osteoblasts. Biochem Biophys Res Commun 1999, 256:419-424. 10.1006/bbrc.1999.0341, 10079200.
19. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534. 10.1126/science.3201241, 3201241.
20. Kaihara S, Bessho K, Okubo Y, Sonobe J, Komatsu Y, Miura M, Miyatake S, Nakao K, Iizuka T. Over expression of bone morphogenetic protein-3b (BMP-3b) using an adenoviral vector promote the osteoblastic differentiation in C2C12 cells and augment the bone formation induced by bone morphogenetic protein-2 (BMP-2) in rats. Life Sci 2003, 72:1683-1693. 10.1016/S0024-3205(02)02477-3, 12559390.
21. Dai Z, Lakshmanan RR, Zhu WG, Smiraglia DJ, Rush LJ, Frühwald MC, Brena RM, Li B, Wright FA, Ross P, Otterson GA, Plass C. Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia 2001, 3:314-323. 10.1038/sj.neo.7900162, 1505864, 11571631.
22. Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, Tannehill-Gregg S, Morrison CD, Auer H, Kratzke RA, Niehans G, Amatschek S, Sommergruber W, Leone GW, Rosol T, Otterson GA, Plass C. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene 2004, 23:3521-3529. 10.1038/sj.onc.1207441, 15116090.
23. Kraunz KS, Nelson HH, Liu M, Wiencke JK, Kelsey KT. Interaction between the bone morphogenetic proteins and Ras/ MAP-kinase signalling pathways in lung cancer. Br J Cancer 2005, 93:949-952. 10.1038/sj.bjc.6602790, 2361658, 16175182.
24. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005, 25:8581-8591. 10.1128/MCB.25.19.8581-8591.2005, 1265732, 16166639.
25. Kimura K, Toyooka S, Tsukuda K, Yamamoto H, Suehisa H, Soh J, Otani H, Kubo T, Aoe K, Fujimoto N, Kishimoto T, Sano Y, Pass HI, Date H. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep 2008, 20:1265-1268.
26. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001, 410:120-124. 10.1038/35065138, 11242054.
27. Nakayama J, Rice JC, Strahl BD, Allis CD, Grewal SI. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001, 292:110-113. 10.1126/science.1060118, 11283354.
28. Choi KY, Kim HJ, Lee MH, Kwon TG, Nah HD, Furuichi T, Komori T, Nam SH, Kim YJ, Kim HJ, Ryoo HM. Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn 2005, 233:115-121. 10.1002/dvdy.20323, 15765505.
29. Dickmeis T, Rastegar S, Aanstad P, Clark M, Fischer N, Korzh V, Strähle U. Expression of the anti-dorsalizing morphogenetic protein gene in the zebrafish embryo. Dev Genes Evol 2001, 211:568-572. 10.1007/s00427-001-0190-3, 11862464.
30. Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 2003, 88:446-454. 10.1002/jcb.10369, 12532321.
31. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005, 102:1454-1459. 10.1073/pnas.0409121102, 547873, 15665096.
32. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006, 25:589-600.
33. Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY, Kuo PL. Lung tumor associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem 2011, 286:37335-37346. 10.1074/jbc.M111.256156, 21885439.
34. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008, 68:7795-7802. 10.1158/0008-5472.CAN-08-1078, 2596479, 18829534.
35. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003, 56:13-22. 10.1002/pros.10233, 12746842.
36. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006, 66:6512-6520. 10.1158/0008-5472.CAN-06-0369, 16818622.
37. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003, 278:48684-48689. 10.1074/jbc.M308001200, 14506237.
38. Leong DT, Lim J, Goh X, Pratap J, Pereira BP, Kwok HS, Nathan SS, Dobson JR, Lian JB, Ito Y, Voorhoeve PM, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res 2010, 12:R89. 10.1186/bcr2762, 3096982, 21029421.
39. Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 2010, 9:258-275. 10.1186/1476-4598-9-258, 2955618, 20863401.
40. Upadhyay G, Yin Y, Yuan H, Li X, Derynck R, Glazer RI. Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-{beta} signaling. Proc Natl Acad Sci USA 2011, 108:7820-7825. 10.1073/pnas.1103441108, 3093514, 21518866.
41. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002, 111:621-633. 10.1016/S0092-8674(02)01111-X, 12464175.
42. Chakraborty S, Sinha KK, Senyuk V, Nucifora G. SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo. Oncogene 2003, 22:5229-5237. 10.1038/sj.onc.1206600, 12917624.
43. Lian JB, Stein JL, Stein GS, van Wijnen AJ, Montecino M, Javed A, Gutierrez S, Shen J, Zaidi SK, Drissi H. Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res 2003, 44(Suppl 1):141-148.
44. Boumah CE, Lee M, Selvamurugan N, Shimizu E, Partridge NC. Runx2 recruits p300 to mediate parathyroid hormone's effects on histone acetylation and transcriptional activation of the matrix metalloproteinase-13 gene. Mol Endocrinol 2009, 8:1255-1263.
45. Young DW, Hassan MQ, Pratap J, Galindo M, Zaidi SK, Lee SH, Yang X, Xie R, Javed A, Underwood JM, Furcinitti P, Imbalzano AN, Penman S, Nickerson JA, Montecino MA, Lian JB, Stein JL, van Wijnen AJ, Stein GS. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 2007, 445:442-446. 10.1038/nature05473, 17251981.
46. Ali SA, Zaidi SK, Dacwag CS, Salma N, Young DW, Shakoori AR, et al. Phenotypic transcription factors epigenetically mediate cell growth control. Proc Natl Acad Sci USA 2008, 105:6632-6637. 10.1073/pnas.0800970105, 2373311, 18445650.
47. Westendorf JJ. Transcriptional co-repressors of Runx2. J Cell Biochem 2006, 98:54-64. 10.1002/jcb.20805, 16440320.
48. Lamour V, Detry C, Sanchez C, Henrotin Y, Castronovo V, Bellahcène A. Runx2-and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem 2007, 282:36240-36249. 10.1074/jbc.M705833200, 17956871.
49. McGee-Lawrence ME, Bradley EW, Westendorf JJ. Hdac-mediated control of endochondral and intramembranous ossification. Crit Rev Eukaryot Gene Expr 2011, 21:101-113. 3218555, 22077150.